Track topics on Twitter Track topics that are important to you
Avexxin is a pharmaceutical company focused on developing and commercializing novel small molecule therapeutics for patients with chronic inflammatory conditions. Avexxin's advanced understanding of the biology of the inflammatory process has resulted in a novel therapeutic approach for the treatment of psoriasis and other inflammatory disorders. Our discovery and clinical development expertise is focused on providing disease-modifying drugs addressing inflammatory disorders that are not adequately treated with existing therapies
Norwegian University of Science and TechnologyHøgskoleringen 5
Phone: 47 73 59 61 07
Fax: 47 73 59 61 00
Avexxin is a clinical-stage pharmaceutical company focused on developing a novel first-in-class small molecule platform for the treatment of inflammatory diseases. Michael Orum, president and CEO of A...
Avexxin is a pharmaceutical company focused on developing and commercializing novel small molecule therapeutics for patients with chronic inflammatory conditions. Avexxin's advanced understanding of t...
We have published hundreds of Avexxin news stories on BioPortfolio along with dozens of Avexxin Clinical Trials and PubMed Articles about Avexxin for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Avexxin Companies in our database. You can also find out about relevant Avexxin Drugs and Medications on this site too.
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...